Matthew Parris

Director Técnico/Científico/I+D en TRAWS PHARMA, INC. .

Health Technology

Consumer Services

Cargos activos de Matthew Parris

Empresas	Cargo	Inicio	Fin
TRAWS PHARMA, INC.	Director Técnico/Científico/I+D	01/08/2018	-

Empresas	Cargo	Inicio	Fin
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Corporate Officer/Principal	-	-
AEGERION PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-
INOVIO PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-

Imperial College London

Undergraduate Degree

Internacional

Estados Unidos	5
Reino Unido	2

Operativa

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sectorial

Health Technology	5
Consumer Services	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	2
TRAWS PHARMA, INC.	Health Technology
INOVIO PHARMACEUTICALS, INC.	Health Technology

Empresas privadas	2
Eleison Pharmaceuticals, Inc. Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ.	Health Technology
Aegerion Pharmaceuticals, Inc. Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA.	Health Technology

Empresas privadas

Health Technology